Carlyle Group Inc. - Aug 28, 2025 SCHEDULE 13G/A Report for Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (PHAT)

Filing Manager
Carlyle Group Inc.
Reporting Manager
Carlyle Group Inc.
Security
Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share
Symbol
PHAT
Shares outstanding
71.4M shares
Disclosed Ownership
3.5M shares
Ownership
4.9%
Form type
SCHEDULE 13G/A
Date filed
8/28/2025, 04:30 PM
Date of event
Aug 28, 2025
SEC
View on sec.gov

Reporting Managers (11)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Carlyle Group Inc. 4.9% 3.5M 0 3.5M /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Carlyle Holdings I GP Inc. 4.9% 3.5M 0 3.5M /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director and Chief Financial Officer
Carlyle Holdings I GP Sub L.L.C. 4.9% 3.5M 0 3.5M By: Carlyle Holdings I GP Inc., its sole member, By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director and Chief Financial Officer
Carlyle Holdings I L.P. 4.9% 3.5M 0 3.5M /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
CG Subsidiary Holdings L.L.C. 4.9% 3.5M 0 3.5M /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
TC Group, L.L.C. 4.9% 3.5M 0 3.5M /s/ Anne Frederick, Attorney-in-fact John C. Redett, Managing Director
Carlyle Investment Management L.L.C. 4.9% 3.5M 0 3.5M By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Carlyle Genesis UK LLC 4.9% 3.5M 0 3.5M By: Carlyle Investment Management L.L.C., its sole member, By: /s/ Anne Frederick, Attorney-in-fact John C. Redett, Chief Financial Officer
Abingworth LLP 4.9% 3.5M 0 3.5M By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory
Abingworth Bioventures 8 LP 2.9% 2.06M 0 2.06M By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory
Abingworth Bioventures VII LP 2% 1.44M 0 1.44M By: /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory